A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT ID: NCT06703021
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
82 participants
INTERVENTIONAL
2024-12-20
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843
Aleniglipron Phase 2 Body Composition Study
NCT07169942
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
NCT06139055
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT06500429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sentinel
Participants will receive aleniglipron or placebo administered orally.
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
Cohort 1a
Participants will receive aleniglipron or placebo administered orally.
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
Cohort 1b
Participants will receive aleniglipron or placebo administered orally.
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
Cohort 1c
Participants will receive aleniglipron or placebo administered orally.
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
aleniglipron or placebo
Drug: aleniglipron administered orally; Drug: placebo administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity
Exclusion Criteria
* Self-reported change in body weight \>5% within 3 months before Screening
* Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
* Use of medications intended to promote weight loss, within 6 months prior to Screening
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACCESS II Research Site
Glendale, California, United States
ACCESS II Research Site
Montclair, California, United States
ACCESS II Research Site
Valparaiso, Indiana, United States
ACCESS II Research Site
West Des Moines, Iowa, United States
ACCESS II Research Site
Medford, Oregon, United States
ACCESS II Research Site
East Greenwich, Rhode Island, United States
ACCESS II Research Site
North Charleston, South Carolina, United States
ACCESS II Research Site
Dallas, Texas, United States
ACCESS II Research Site
San Antonio, Texas, United States
ACCESS II Research Site
West Jordan, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GSBR-1290-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.